X

Bilcare Ltd. Stock Analysis

Small Cap
Evaluated by 1730 users | BSE: 526853 | NSE: |
Plastic Products
Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 9.25%8.74%5.82%-1.99%-4.71%-2.79%-5.36%-15.23%-22.3%-7.71%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 659753727401331315286258240212
Y-o-Y Gr. Rt.-14.3%-3.3%-44.8%-17.5%-4.8%-9.5%-9.8%-6.9%-11.7%
Adjusted EPS (Rs.) 38.9834.1118.38-62.45-78.19-29.65-48.99-106.68-133.29-49.97
Y-o-Y Gr. Rt.--12.5%-46.1%-439.8%NANANANANANA
Book Value per Share (Rs.) 382.4405.53411.13363.04283.29264.39236.34202.4368.5625.13
Adjusted Net Profit 91.880.343.3-147-184-69.8-115-251-314-118
Net Op. Cash Flow (Rs. Cr.) 1047.9144177-16.728.437.37.262.171.1
Debt to Cash Flow from Ops 5.8881.829.626.93-69.0434.3124.1119.4113.979.96
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Bilcare Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -11.9%-8.6%-9.5%-11.7%
Adjusted EPS -202.8%NANANA
Book Value per Share -26.1-38.4-52.6-63.4
Share Price -20.1% -1.6% -7% 80.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 10.918.664.5-16.13-24.2-10.83-19.57-48.63-98.38-106.67
Operating Profit Margin (%) 30.4729.5825.216.046.358.57-10.40.82-2.56
Net Profit Margin (%) 13.9310.675.95-36.64-55.57-22.13-40.39-97.54-130.87-55.56
Debt to Equity 0.680.681.431.441.731.571.611.85.3711.97
Working Capital Days 211236282477592448278290300346
Cash Conversion Cycle 14418414916121214061645336
Entity Percentage Holding
Promoters 30.01%
Institutions 0.04%
Non-Institutions 69.94%
Pledged *1.391.391.391.391.391.391.391.391.391.39
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Bilcare Ltd.'s performance infers:

Bilcare Ltd. earnings have grown by 0%, whereas share price has depreciated -1.6% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Bilcare Ltd. share prices over the last 10 years. Here is what we found out:

Bilcare Ltd. share price has depreciated -24.9% annually over the past ten years.

Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and

Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.

Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.

Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.

Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security
The company develops design keeping various aspects into consideration such as end-user, optimum material, composite dosages, on-pack communication, cost-effective, regulatory requirements, etc.It also offers pharmaceutical research and clinical services.

It has representative offices located in Argentina, Bangladesh, Chile, Colombia, Czech Republic, Egypt, France, Indonesia, Iran, Israel, Italy, Jordan, South Korea, Malaysia, Mexico, Pakistan, Saudi Arabia, South Africa, Spain, Taiwan, Thailand, Turkey, Venezuela and Vietnam.

It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddy’s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide.

For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites.

Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs.

In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback